TherapeuticsMD, Inc. Operating Income Loss

• TherapeuticsMD, Inc. showed an increase of +28.2% in Operating Income Loss from 2024 to 2025.
• This data is from TherapeuticsMD, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 15 years of available data (2011 to 2025), TherapeuticsMD, Inc.'s Operating Income Loss has grown by 19.1%.
• Historical annual values: Fiscal year 2025: -$4.39 million | Fiscal year 2024: -$6.11 million | Fiscal year 2023: -$8.52 million | Fiscal year 2022: $1.19 million | Fiscal year 2021: -$79.58 million | Fiscal year 2020: -$155.54 million | Fiscal year 2019: -$151.21 million | Fiscal year 2018: -$130.22 million | Fiscal year 2017: -$77.63 million | Fiscal year 2016: -$90.25 million | Fiscal year 2015: -$85.19 million | Fiscal year 2014: -$54.04 million | Fiscal year 2013: -$25.81 million | Fiscal year 2012: -$16.15 million | Fiscal year 2011: -$5.43 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026